BioWorld Science

May 2, 2014

View Archived Issues

NKTT-320 activates immunostimulatory functions of human iNKTs

Read More

RP-5063 shows robust efficacy and safety in phase II REFRESH trial

Read More

Roche and NCI present preclinical data for RG-7787

Read More

New grant to support phase I/II trial of OXB-102 gene therapy for Parkinson's disease

Read More

RXi enrolls first patient in phase IIa keloid scar trial

Read More

Lilly nociceptin receptor antagonist proves useful for various conditions

Read More

MEI Pharma presents novel PI3Kdelta inhibitors

Read More

Vertex Pharmaceuticals synthesizes novel mannose derivatives

Read More

Advinus Therapeutics prepares novel DGAT1 inhibitors for diabetes and other disorders

Read More

InterMune selects new agents for fibrotic disorders

Read More

Allena Pharmaceuticals reports phase I data for ALLN-177

Read More

Akers Biosciences begins trials for Chlamydia assay

Read More

Vizamyl to be launched in U.S. in late 2Q 2014

Read More

Oricula Therapeutics receives NIH grant to further develop medicine to preserve hearing

Read More

Sotatercept obtains FDA orphan drug designation

Read More

Silence Therapeutics shows gene knockdown in non-human primates

Read More

Parion Sciences regains rights to ENaC inhibitors

Read More

First patient dosed in phase III study of Pulmaquin in non-cystic fibrosis bronchiectasis

Read More

Phase III program for mepolizumab in COPD begins

Read More

Favorable pharmacokinetics and pharmacodynamic activity of RPC-1063 in human volunteers

Read More

AstraZeneca offers overview of first quarter 2014

Read More

Forest Laboratories to acquire Furiex Pharmaceuticals

Read More

Ono and Nissan Chemical discontinue license agreement

Read More

FDA issues complete response letter regarding cangrelor NDA

Read More

GSK's inhaled umeclidinium approved in U.S.

Read More